GO:0004331 fructose-2,6-bisphosphate 2-phosphatase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004331 describes the enzymatic activity that removes the 2-phosphate from D-fructose 2,6-bisphosphate, yielding D-fructose-6-phosphate and phosphate.
• This activity is one half of the bifunctional enzyme family 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB1-4), which controls the cellular level of the glycolysis activator fructose-2,6-bisphosphate.
• The phosphatase reaction lowers fructose-2,6-bisphosphate, thereby reducing phosphofructokinase-1 (PFK-1) activity and dampening glycolytic flux.
• PFKFB3 is the most studied isoform in disease; its kinase activity is often dominant in cancer, fibrosis and angiogenesis, while the phosphatase activity provides an off-switch.
• Dysregulated fructose-2,6-bisphosphate turnover is linked to kidney fibrosis, pulmonary fibrosis, diabetic kidney disease, vessel sprouting and tumor cell glycolysis.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to separate the kinase and phosphatase activities of PFKFB enzymes in a given cell type.
Description
Fructose-2,6-bisphosphate 2-phosphatase activity (GO:0004331) is a molecular function that catalyzes the hydrolysis of D-fructose 2,6-bisphosphate to D-fructose-6-phosphate and phosphate. This reaction is the reverse of the kinase half-reaction carried out by the same bifunctional enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB), and together the two activities set the steady-state concentration of fructose-2,6-bisphosphate, the most potent allosteric activator of phosphofructokinase-1 (PFK-1). Because fructose-2,6-bisphosphate strongly stimulates glycolysis and inhibits gluconeogenesis, the phosphatase activity encoded by GO:0004331 acts as a brake on glycolytic flux. Researchers study this activity to understand how cells switch between glycolytic and oxidative metabolism, and how that switch is corrupted in cancer, fibrosis and metabolic disease. The QuickGO definition is deliberately narrow: it covers only the hydrolysis of D-fructose 2,6-bisphosphate, not the kinase reaction that produces it, and not the downstream glycolytic enzymes. This distinction matters because the bifunctional PFKFB proteins are often described as a single unit, yet their kinase and phosphatase activities can be independently regulated and can have opposite effects on cell metabolism. In this article we focus strictly on GO:0004331, its catalytic mechanism, the genes that carry it, the diseases in which it is implicated, and the CRISPR-based methods used to study it.
fructose-2,6-bisphosphate 2-phosphatase activity At A Glance
| GO ID | GO:0004331 |
|---|---|
| GO term | fructose-2,6-bisphosphate 2-phosphatase activity |
| Ontology | molecular_function |
| Synonym | beta-D-fructose-2,6-bisphosphate 2-phosphohydrolase activity; D-fructose-2,6-bisphosphate 2-phosphohydrolase activity; fructose-2,6-bisphosphatase activity |
| Major function | Hydrolysis of D-fructose 2,6-bisphosphate to D-fructose-6-phosphate and phosphate, reducing the cellular level of the glycolysis activator fructose-2,6-bisphosphate |
| Enzyme family | Bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB1-4) |
| Substrate | D-fructose 2,6-bisphosphate |
| Products | D-fructose-6-phosphate and phosphate |
| Pathway context | Regulation of glycolysis and gluconeogenesis via fructose-2,6-bisphosphate levels |
What Is GO:0004331?
GO:0004331, fructose-2,6-bisphosphate 2-phosphatase activity, is defined as the catalysis of the reaction: D-fructose 2,6-bisphosphate + H2O = D-fructose-6-phosphate + phosphate. In plain terms, it is the enzyme activity that cuts the phosphate group at position 2 off fructose-2,6-bisphosphate, converting it back to fructose-6-phosphate and free phosphate. This activity is one of the two catalytic functions of the bifunctional PFKFB enzymes and is distinct from the 6-phosphofructo-2-kinase activity that synthesizes fructose-2,6-bisphosphate.
Why Is fructose-2,6-bisphosphate 2-phosphatase activity Important in Cell Biology?
GO:0004331 is important because it provides the off-switch for fructose-2,6-bisphosphate, the metabolite that determines whether a cell runs glycolysis at high or low speed. By removing the 2-phosphate, the phosphatase activity lowers fructose-2,6-bisphosphate, reduces PFK-1 activation and shifts metabolism away from glycolysis. This makes the activity central to physiological processes such as vessel sprouting, where PFKFB3-driven glycolysis is required for endothelial cell proliferation, and to pathological processes such as kidney fibrosis, pulmonary fibrosis and diabetic kidney disease, where PFKFB3-mediated glycolysis promotes disease progression. Understanding GO:0004331 therefore helps researchers interpret metabolic reprogramming in cancer and fibrosis and design experiments that separate the kinase and phosphatase arms of PFKFB enzymes.
• Controls the cellular concentration of fructose-2,6-bisphosphate, the strongest allosteric activator of PFK-1.
• Acts as a brake on glycolytic flux and supports gluconeogenesis when the phosphatase activity dominates.
• Is one of the two catalytic activities of the bifunctional PFKFB enzymes, making it a key node in metabolic regulation.
• PFKFB3-driven glycolysis promotes kidney fibrosis through histone lactylation-mediated NF-kB activation, a process in which fructose-2,6-bisphosphate turnover is central.
• PFKFB3-mediated glycolysis in lung fibroblasts contributes to collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis.
• PFKFB3-mediated endothelial glycolysis promotes diabetic kidney disease progression.
• PFKFB3-driven glycolysis is required for vessel sprouting, linking GO:0004331 to angiogenesis.
• Tumor cells often rely on high fructose-2,6-bisphosphate levels, making the phosphatase activity a potential target for metabolic intervention.
• mTOR signaling can boost glycolysis during cell cycle entry, a context in which fructose-2,6-bisphosphate turnover is relevant.
• CRISPR models allow researchers to dissect the phosphatase activity from the kinase activity of PFKFB enzymes in disease-relevant cell types.
Molecular Mechanism of fructose-2,6-bisphosphate 2-phosphatase activity
Substrate recognition and binding
In simple terms: The enzyme grabs fructose-2,6-bisphosphate and holds it in place so the 2-phosphate can be removed.
The substrate of GO:0004331 is D-fructose 2,6-bisphosphate, a metabolite that carries phosphate groups at both the 2 and 6 positions. The phosphatase active site of the bifunctional PFKFB enzyme binds this substrate and positions the 2-phosphate for hydrolysis, while leaving the 6-phosphate intact. This selectivity is what distinguishes the phosphatase activity from the kinase activity of the same protein, which instead adds a phosphate to fructose-6-phosphate.
Catalytic hydrolysis
In simple terms: Water is used to cut off the 2-phosphate, releasing fructose-6-phosphate and free phosphate.
The reaction catalyzed by GO:0004331 is D-fructose 2,6-bisphosphate + H2O = D-fructose-6-phosphate + phosphate. Hydrolysis of the phosphoester bond at position 2 releases inorganic phosphate and leaves D-fructose-6-phosphate, which can re-enter the glycolytic or gluconeogenic pathways. This reaction is the reverse of the 6-phosphofructo-2-kinase half-reaction, and the balance between the two activities determines the net level of fructose-2,6-bisphosphate in the cell.
Bifunctional enzyme architecture
In simple terms: The same protein contains both the kinase and the phosphatase, so the two opposing reactions are physically linked.
GO:0004331 is carried out by the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, which contains an N-terminal kinase domain and a C-terminal phosphatase domain. This head-to-head architecture means that synthesis and degradation of fructose-2,6-bisphosphate are catalyzed by the same polypeptide, allowing coordinated regulation. The phosphatase domain is the structural basis for GO:0004331, and its activity can be independently modulated by post-translational modifications and allosteric signals.
Regulation by phosphorylation and allosteric signals
In simple terms: Chemical tags and small molecules can turn the phosphatase up or down without changing how much enzyme is present.
The bifunctional PFKFB enzyme is regulated by phosphorylation, which can shift the balance between its kinase and phosphatase activities. For example, hormonal signals that trigger phosphorylation of PFKFB can favor one activity over the other, thereby changing fructose-2,6-bisphosphate levels and glycolytic flux. In addition, the phosphatase activity is sensitive to the local concentration of its substrate and products, so metabolic state feeds back on GO:0004331.
Integration with glycolysis and gluconeogenesis
In simple terms: By removing the glycolysis activator, the phosphatase helps the cell decide whether to burn or make glucose.
Fructose-2,6-bisphosphate activates PFK-1 and inhibits fructose-1,6-bisphosphatase, so lowering its level via GO:0004331 reduces glycolytic flux and favors gluconeogenesis. This makes the phosphatase activity a key control point in hepatic and other tissues where glucose production and consumption must be balanced. In disease contexts such as fibrosis and cancer, this balance is often disrupted, and PFKFB3-mediated glycolysis can dominate.
Key Genes Involved in GO:0004331 fructose-2,6-bisphosphate 2-phosphatase activity
The genes below encode the enzymes and regulatory proteins most directly associated with fructose-2,6-bisphosphate 2-phosphatase activity (GO:0004331) and its metabolic context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PFKFB1 | Bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 1; carries GO:0004331 phosphatase activity | Studied for its role in hepatic glucose metabolism and the balance between glycolysis and gluconeogenesis |
| PFKFB2 | Bifunctional PFKFB isoform 2; contains the phosphatase domain responsible for GO:0004331 | Investigated in tissues where fructose-2,6-bisphosphate levels are hormonally regulated |
| PFKFB3 | Bifunctional PFKFB isoform 3; kinase activity is often dominant, but the phosphatase domain carries GO:0004331 | Central to cancer glycolysis, fibrosis, angiogenesis and diabetic kidney disease |
| PFKFB4 | Bifunctional PFKFB isoform 4; includes the phosphatase activity of GO:0004331 | Studied in metabolic reprogramming and tumor cell glycolysis |
| PFK-1 | Phosphofructokinase-1, the glycolytic enzyme activated by fructose-2,6-bisphosphate | Readout of the metabolic impact of GO:0004331 activity |
| FBPase | Fructose-1,6-bisphosphatase, inhibited by fructose-2,6-bisphosphate | Relevant to gluconeogenesis when GO:0004331 lowers fructose-2,6-bisphosphate |
| mTOR | Signaling kinase that can boost glycolysis during cell cycle entry | Context for how fructose-2,6-bisphosphate turnover is coupled to growth signals |
| IGFBP5 | Secreted protein that promotes diabetic kidney disease by enhancing PFKFB3-mediated endothelial glycolysis | Model for studying PFKFB3-driven metabolic disease |
| NF-kB | Transcription factor family activated downstream of PFKFB3-driven glycolysis in kidney fibrosis | Links GO:0004331-related metabolism to inflammatory gene expression |
| Collagen | Extracellular matrix protein whose synthesis is promoted by PFKFB3-mediated glycolysis in lung fibroblasts | Readout for fibrosis models involving PFKFB3 |
| VEGFR2 | Receptor whose signaling supports PFKFB3-driven glycolysis in vessel sprouting | Context for angiogenesis studies |
| APC/C | E3 ubiquitin ligase whose transient inactivation by mTOR boosts glycolysis during cell cycle entry | Connects cell cycle machinery to glycolytic regulation |
| LDHA | Lactate dehydrogenase A, a glycolytic enzyme downstream of fructose-2,6-bisphosphate signaling | Marker of glycolytic flux in PFKFB3-related disease models |
| HIF-1alpha | Hypoxia-inducible factor that can influence glycolytic gene expression | Context for tumor cell glycolysis studies |
| PKM2 | Pyruvate kinase M2, a glycolytic enzyme often studied alongside PFKFB3 | Marker of metabolic reprogramming in cancer |
| GLUT1 | Glucose transporter often upregulated in glycolytic cells | Readout of glycolytic phenotype in PFKFB3 models |
| Fructose-2,6-bisphosphate | Metabolite whose level is set by the balance of PFKFB kinase and GO:0004331 phosphatase activities | Central metabolite for measuring the impact of GO:0004331 |
How Is fructose-2,6-bisphosphate 2-phosphatase activity Regulated?
The activity described by GO:0004331 is regulated at multiple levels. The bifunctional PFKFB enzyme is subject to phosphorylation, which can shift the balance between its kinase and phosphatase activities and thereby change fructose-2,6-bisphosphate levels. Hormonal and growth-factor signals that converge on PFKFB enzymes can favor either the synthesis or the degradation of fructose-2,6-bisphosphate, adjusting glycolytic flux to the metabolic needs of the cell. In addition, mTOR signaling can boost glycolysis during cell cycle entry, providing a context in which fructose-2,6-bisphosphate turnover is coupled to proliferative signals. In disease states such as fibrosis and cancer, PFKFB3 expression and activity are often elevated, and the phosphatase activity of GO:0004331 provides a potential counterbalance to excessive glycolysis.
fructose-2,6-bisphosphate 2-phosphatase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PFKFB3 | Kidney fibrosis via histone lactylation-mediated NF-kB activation | PFKFB3 knockout or point-mutant kidney fibroblast models |
| PFKFB3 | Pulmonary fibrosis and collagen synthesis in lung fibroblasts | PFKFB3 overexpression or knockout in lung fibroblast cultures |
| PFKFB3 | Diabetic kidney disease and endothelial glycolysis | Endothelial cells with PFKFB3 knockdown or knockout under high-glucose conditions |
| PFKFB3 | Vessel sprouting and angiogenesis | Endothelial spheroid sprouting assays with PFKFB3 loss- or gain-of-function |
| PFKFB3 | Tumor cell glycolysis | Cancer cell lines with PFKFB3 knockout or phosphatase-dead mutants |
Kidney fibrosis and PFKFB3-driven glycolysis
PFKFB3 drives kidney fibrosis through promoting histone lactylation-mediated NF-kB family activation, a process that depends on glycolytic flux controlled in part by fructose-2,6-bisphosphate turnover. The phosphatase activity of GO:0004331 would be expected to lower fructose-2,6-bisphosphate and dampen this glycolytic drive, making it relevant to fibrosis research.
Pulmonary fibrosis and fibroblast glycolysis
The PI3K-Akt-mTOR/PFKFB3 pathway mediates lung fibroblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis. This links PFKFB3 activity, and by extension the balance with GO:0004331, to extracellular matrix deposition in the lung.
Diabetic kidney disease and endothelial glycolysis
IGFBP5 promotes diabetic kidney disease progression by enhancing PFKFB3-mediated endothelial glycolysis. The phosphatase activity of GO:0004331 is part of the same metabolic node, and its modulation could influence endothelial metabolic dysfunction in diabetic kidney disease.
Cancer and tumor cell glycolysis
PFKFB enzymes and tumor cell glycolysis are closely linked, with fructose-2,6-bisphosphate levels supporting high glycolytic rates in cancer cells. The phosphatase activity of GO:0004331 provides a potential brake on this process, making it a subject of interest for metabolic targeting in oncology.
From fructose-2,6-bisphosphate 2-phosphatase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PFKFB3 phosphatase activity change fructose-2,6-bisphosphate levels? | CRISPR knockout of the PFKFB3 phosphatase domain or point mutation of catalytic residues |
| Can a phosphatase-dead PFKFB3 mutant separate kinase from phosphatase functions? | Point-mutation knock-in of catalytically inactive phosphatase residues |
| Does restoring phosphatase activity rescue a glycolytic phenotype? | Knock-in of wild-type phosphatase domain or overexpression of PFKFB3 |
| How does PFKFB3-driven glycolysis affect fibrosis markers? | Knockout or overexpression in kidney or lung fibroblast models |
| Is PFKFB3 required for endothelial sprouting? | Endothelial cell knockout or knockdown in spheroid sprouting assays |
| How does mTOR signaling interact with fructose-2,6-bisphosphate turnover? | CRISPR models combined with mTOR pathway perturbation |
How to Study the fructose-2,6-bisphosphate 2-phosphatase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fructose-2,6-bisphosphate quantification | Cellular level of the substrate/product of GO:0004331 | Assessing the impact of PFKFB mutations on glycolytic regulation |
| Phosphatase activity assay | Enzymatic hydrolysis of D-fructose 2,6-bisphosphate | Comparing wild-type and mutant PFKFB enzymes |
| CRISPR knockout | Loss of PFKFB gene function | Testing requirement for PFKFB3 in fibrosis or angiogenesis |
| Point-mutation knock-in | Specific catalytic residue function | Separating phosphatase from kinase activity |
| RNA-seq | Transcriptional changes after PFKFB manipulation | Identifying downstream metabolic and inflammatory pathways |
| Proteomics | Protein abundance and modification changes | Detecting histone lactylation and NF-kB activation |
| Seahorse extracellular flux analysis | Glycolytic and oxidative metabolic rates | Measuring metabolic phenotype in PFKFB3 models |
| Spheroid sprouting assay | Endothelial sprouting capacity | Testing PFKFB3 requirement in angiogenesis |
Metabolite measurement of fructose-2,6-bisphosphate
Direct measurement of fructose-2,6-bisphosphate levels is the most specific way to assess the impact of GO:0004331 activity, because the phosphatase lowers this metabolite. Such measurements can be combined with glycolytic flux assays to link the activity to pathway output.
Enzymatic activity assays
In vitro phosphatase assays using D-fructose 2,6-bisphosphate as substrate can directly measure GO:0004331 activity in cell lysates or purified protein preparations. These assays are useful for comparing wild-type and mutant PFKFB enzymes.
CRISPR-based genetic dissection
CRISPR knockout, point mutation and knock-in models allow researchers to separate the phosphatase activity of GO:0004331 from the kinase activity of the same bifunctional enzyme. This is essential because the two activities have opposite effects on fructose-2,6-bisphosphate levels.
Transcriptomic and proteomic profiling
RNA-seq and proteomics can reveal downstream changes in glycolytic gene expression and protein abundance when PFKFB3 or other PFKFB enzymes are manipulated. These methods help connect GO:0004331 activity to broader metabolic and inflammatory programs.
How CRISPR Can Be Used to Study GO:0004331 fructose-2,6-bisphosphate 2-phosphatase activity
Knockout
CRISPR knockout of PFKFB genes removes both the kinase and phosphatase activities, providing a clean loss-of-function background to test the contribution of GO:0004331 to glycolysis and disease phenotypes. Knockout models have been used to show that PFKFB3-driven glycolysis is required for vessel sprouting and contributes to fibrosis.
Point Mutation
Point mutation of catalytic residues in the phosphatase domain can selectively abolish GO:0004331 activity while preserving the kinase activity of the bifunctional enzyme. Such mutants are valuable for separating the two opposing reactions in metabolic studies.
Knock-in
Knock-in of wild-type or mutant PFKFB alleles allows researchers to restore or modify phosphatase activity in a controlled manner. This approach can test whether the phosphatase activity of GO:0004331 is sufficient to reverse a glycolytic phenotype.
Overexpression
Overexpression of PFKFB3 or other PFKFB isoforms can increase fructose-2,6-bisphosphate turnover and drive glycolysis, modeling the metabolic state seen in cancer and fibrosis. Overexpression models are useful for testing whether increased phosphatase activity can counteract disease-associated glycolysis.
How EDITGENE Supports fructose-2,6-bisphosphate 2-phosphatase activity Research
Researchers studying fructose-2,6-bisphosphate 2-phosphatase activity-related genes often need to determine whether a candidate gene is causally involved in a metabolic or disease phenotype, and CRISPR-based models provide the most direct way to test that causality. EDITGENE offers a suite of services designed to support such studies, from knockout and point-mutation models to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for fructose-2,6-bisphosphate 2-phosphatase activity research.
Frequently Asked Questions About fructose-2,6-bisphosphate 2-phosphatase activity
What is fructose-2,6-bisphosphate 2-phosphatase activity?
It is the enzymatic activity defined by GO:0004331 that catalyzes the hydrolysis of D-fructose 2,6-bisphosphate to D-fructose-6-phosphate and phosphate.
What genes are involved in fructose-2,6-bisphosphate 2-phosphatase activity?
The activity is carried by the bifunctional PFKFB enzyme family, including PFKFB1, PFKFB2, PFKFB3 and PFKFB4.
What is the reaction catalyzed by GO:0004331?
The reaction is D-fructose 2,6-bisphosphate + H2O = D-fructose-6-phosphate + phosphate.
How does fructose-2,6-bisphosphate 2-phosphatase activity affect glycolysis?
By lowering fructose-2,6-bisphosphate, the phosphatase activity reduces activation of PFK-1 and dampens glycolytic flux.
Which diseases are linked to PFKFB3 and fructose-2,6-bisphosphate turnover?
PFKFB3-driven glycolysis has been linked to kidney fibrosis, pulmonary fibrosis, diabetic kidney disease, vessel sprouting and tumor cell glycolysis.
How can I study GO:0004331 in the lab?
Direct measurement of fructose-2,6-bisphosphate, phosphatase activity assays, and CRISPR knockout or point-mutation models are common approaches.
What is the difference between PFKFB kinase and phosphatase activities?
The kinase activity synthesizes fructose-2,6-bisphosphate, while the phosphatase activity of GO:0004331 degrades it, and both are carried by the same bifunctional enzyme.
Can CRISPR separate the two activities of PFKFB enzymes?
Yes, point mutations that selectively inactivate the phosphatase domain can separate GO:0004331 from the kinase activity.
Why is fructose-2,6-bisphosphate important in cancer?
Tumor cells often rely on high glycolytic rates, and fructose-2,6-bisphosphate supports PFK-1 activity, making its turnover relevant to cancer metabolism.
Does mTOR signaling regulate fructose-2,6-bisphosphate levels?
mTOR signaling can boost glycolysis during cell cycle entry, providing a context in which fructose-2,6-bisphosphate turnover is coupled to growth signals.
Conclusion
GO:0004331, fructose-2,6-bisphosphate 2-phosphatase activity, is a narrowly defined but metabolically powerful enzymatic activity that lowers fructose-2,6-bisphosphate and thereby modulates glycolysis. It is carried by the bifunctional PFKFB enzymes, whose kinase and phosphatase activities have opposite effects on metabolic flux. The activity is implicated in kidney fibrosis, pulmonary fibrosis, diabetic kidney disease, angiogenesis and cancer metabolism, making it a compelling target for CRISPR-based functional studies. By combining precise genetic models with metabolic and transcriptomic readouts, researchers can dissect how GO:0004331 contributes to health and disease.
References
- 1. Wang Y et al.. 2024. The glycolytic enzyme PFKFB3 drives kidney fibrosis through promoting histone lactylation-mediated NF-κB family activation.. Kidney Int 106(2):226-240 PMID: 38789037
- 2. Chesney J. 2006. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis.. Curr Opin Clin Nutr Metab Care 9(5):535-9 PMID: 16912547
- 3. Rider MH et al.. 2004. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis.. Biochem J 381(Pt 3):561-79 PMID: 15170386
- 4. van Schaftingen E et al.. 1982. Fructose-2,6-bisphosphatase from rat liver.. Eur J Biochem 124(1):143-9 PMID: 6282585
- 5. De Bock K et al.. 2013. Role of PFKFB3-driven glycolysis in vessel sprouting.. Cell 154(3):651-63 PMID: 23911327
- 6. Hu X et al.. 2020. PI3K-Akt-mTOR/PFKFB3 pathway mediated lung fibroblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis.. Lab Invest 100(6):801-811 PMID: 32051533
- 7. Paul D et al.. 2025. Transient APC/C inactivation by mTOR boosts glycolysis during cell cycle entry.. Nature 646(8083):198-207 PMID: 40739344
- 8. Song C et al.. 2022. IGFBP5 promotes diabetic kidney disease progression by enhancing PFKFB3-mediated endothelial glycolysis.. Cell Death Dis 13(4):340 PMID: 35418167
